Scarica l'app Stockscreener
0.00
100.00%
-2.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AADI Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.05
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$94.89M
Reddito:
$23.26M
Utile/perdita netta:
$-63.41M
Rapporto P/E:
0.00
EPS:
-2.36
Flusso di cassa netto:
$-64.56M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$3.812
Aadi Bioscience Inc Stock (AADI) Company Profile
Nome
Aadi Bioscience Inc
Settore
Industria
Telefono
424-473-8055
Indirizzo
17383 SUNSET AVENUE, PACIFIC PALISADES
Confronta AADI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AADI
Aadi Bioscience Inc
|
0.00 | 94.89M | 23.26M | -63.41M | -64.56M | -2.36 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-27 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | Downgrade | Jefferies | Buy → Hold |
| 2024-08-21 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | Iniziato | Jefferies | Buy |
| 2021-10-01 | Iniziato | Cowen | Outperform |
| 2021-09-14 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-09-08 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Aadi Bioscience Inc Borsa (AADI) Ultime notizie
Reviewing Aadi Bioscience (NASDAQ:AADI) & UCB (OTCMKTS:UCBJF) - Defense World
Whitehawk Therapeutics Reports Strong Q1 2025 Results - TipRanks
Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights - PR Newswire
Geode Capital Management LLC Purchases 8,546 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World
Aadi Bioscience (NASDAQ:AADI) Trading Down 0.6% – Should You Sell? - Defense World
Ten March deals passed $1B, totaling $25.31B in value - BioWorld MedTech
Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent
Analyzing Aadi Bioscience (NASDAQ:AADI) and Orgenesis (NASDAQ:ORGS) - Defense World
Whitehawk Therapeutics - The Pharma Letter
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations - MarketScreener
Aadi Bioscience to Participate at Upcoming Investor Conferences - MarketScreener
Aadi Bioscience to Participate in Upcoming Investor Events - MarketScreener
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - MarketScreener
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting - MarketScreener
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference - MarketScreener
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes - MarketScreener
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $5.2M - MarketScreener
Aadi Bioscience, (AADI) reports earnings - Quartz
Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals - citybiz
Whitehawk Therapeutics sells subsidiary for $102.4 million - Investing.com Australia
Whitehawk Therapeutics sells subsidiary for $102.4 million By Investing.com - Investing.com Canada
Whitehawk sells Aadi Subsidiary to Kaken for $100 million - Investing.com
Whitehawk sells Aadi Subsidiary to Kaken for $100 million By Investing.com - Investing.com India
Whitehawk Therapeutics Completes Strategic Transformation With Successful Closing Of Sale Of Aadi Subsidiary To Kaken Pharmaceuticals - Marketscreener.com
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - The Victoria Advocate
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing - MarketScreener
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences - MarketScreener
Aadi Bioscience Announces Leadership Transition - MarketScreener
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium - MarketScreener
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2024 Earnings Call Transcript - Insider Monkey
Aadi Bioscience’s Earnings Call: Strategic Shifts and Promising Pipeline - TipRanks
Suvretta Capital Management, LLC Acquires Significant Stake in A - GuruFocus
Aadi Bioscience Announces Approval of All Proposals at Special M - GuruFocus.com
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - MarketScreener
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update - Marketscreener.com
HC Wainwright Adjusts Price Target on Aadi Bioscience to $45 From $48, Maintains Buy Rating - MarketScreener
Aadi Bioscience, Inc. Announces CEO Changes - MarketScreener
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) - Marketscreener.com
Aadi Bioscience to Participate in the Jefferies Healthcare Conference - MarketScreener
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders - Marketscreener.com
Aadi Bioscience Inc (AADI) Q4 2024 Earnings Call Highlights: Strategic Transition and Financial ... By GuruFocus - Investing.com Canada
Whitehawk Therapeutics: Strategic Shift and Financial Outlook - TipRanks
Aadi rebrands as Whitehawk Therapeutics in new ADC focus - The Pharma Letter
Aadi Bioscience, Inc. will Change its Name to Whitehawk Therapeutics, Inc -March 19, 2025 at 12:00 am EDT - Marketscreener.com
Aadi Bioscience earnings missed by $0.46, revenue fell short of estimates - Investing.com UK
Aadi Bioscience Inc changes name to Whitehawk Therapeutics -March 18, 2025 at 05:58 pm EDT - Marketscreener.com
Aadi Bioscience Inc changes name to Whitehawk Therapeutics - TradingView
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company - PR Newswire
Major Transformation: Aadi Becomes Whitehawk with $180M War Chest for ADC Cancer Programs - Stock Titan
AADI BIOSCIENCE Earnings Preview: Recent $AADI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Aadi Bioscience Inc Azioni (AADI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):